ClinicalTrials.gg
CompletedNCT00464269Updated Jul 21, 2022Results posted

Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures

A Phase 3 interventional study of Placebo and Brivaracetam 2.5 mg in Epilepsy, sponsored by UCB Pharma. Completed at 70 sites in 5 countries. Open to participants aged 16 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-07-21.

Sponsored by UCB Pharma (part of UCB S.A.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
16 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies testing brivaracetam in Epilepsy — 2 open to participants now, 2 under way, 1 of them phase 3. brivaracetam · Epilepsy.

Enrollment
7th of 34
400 · median 94
Started
2007
with 2 others
Phase 3
21 of 34
1 open now
Registered
8th of 34
by date
Lead sponsor
13 of 34
UCB Pharma

Among the 34 studies testing brivaracetam in Epilepsy, this one is the 7th largest by enrollment, is one of 3 that started in 2007, is one of 21 in phase 3, and was the 8th registered.

Epilepsy

1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.

Browse Epilepsy studies →

Open to participants now

2 of the 34 studies testing brivaracetam in Epilepsy are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About brivaracetam

brivaracetam: first FDA approval 2016 (BRIVIACT), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 284 Epilepsy studies recruiting now, 114 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.

This study: 16 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing brivaracetam in Epilepsy, or all of them as a file.
02

Study summary

This study will evaluate the efficacy and safety of Brivaracetam to support the submission file in the indication of adjunctive treatment in adolescents and adults with partial onset seizures.

03

Conditions studied

  • Epilepsy

Browse trials for

Keywords

  • Epilepsy
  • Brivaracetam
  • Partial Onset Seizures, Adolescents & Adults
04

Who can participate

Ages eligible
16 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects were 16 to 70 years, both inclusive. Subjects under 18 years of age were only included where legally permitted and ethically accepted
  • Subjects with well-characterized focal epilepsy or epileptic syndrome according to the International League Against Epilepsy (ILAE) classification
  • Subjects had a history of partial onset seizures (POS) whether or not secondarily generalized (Type I seizures according to the ILAE classification)
  • Subjects had at least 2 POS whether or not secondarily generalized per month during the 3 months preceding Visit 1 (V1)
  • Subjects had at least 8 POS whether or not secondarily generalized during the 8-Week Baseline Period
  • Subjects were uncontrolled while treated by 1 to 2 permitted concomitant antiepileptic drug(s) (AEDs). Vagal nerve stimulation (VNS) was allowed and was not counted as a concomitant AED

Exclusion criteria

Exclusion Criteria:

  • History or presence of seizures occurring only in clusters (too frequently or indistinctly separated to be reliably counted) before Visit 3
  • History or presence of status epilepticus during the year preceding Visit 1 or during Baseline
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
400 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Matching Placebo tablets administered twice a day. Daily oral dose of two equal intakes, morning and evening, of Placebo in a double-blinded way for the 12-week Treatment Period.

    Other: Placebo

  • Experimental
    Brivaracetam 5 mg/day

    Brivaracetam 5 mg/day, 2.5 mg administered twice a day. Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 5 mg /day in a double-blinded way for the 12-week Treatment Period.

    Drug: Brivaracetam 2.5 mg

  • Experimental
    BRV 20mg/day

    Brivaracetam 20 mg/day, 10 mg administered twice a day. Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 20 mg /day in a double-blinded way for the 12-week Treatment Period.

    Drug: Brivaracetam 10 mg

  • Experimental
    BRV 50mg/day

    Brivaracetam 50 mg/day, 25 mg administered twice a day. Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 50 mg /day, in a double-blinded way for the 12-week Treatment Period.

    Drug: Brivaracetam 25 mg

Interventions

  • OtherPlacebo

    * Active Substance: Placebo * Pharmaceutical Form: Film-coated tablet * Concentration: 2.5 mg, 10 mg and 25 mg * Route of Administration: Oral use

  • * Active Substance: Brivaracetam * Pharmaceutical Form: Film-coated tablet * Concentration: 2.5 mg * Route of Administration: Oral use

  • * Active Substance: Brivaracetam * Pharmaceutical Form: Film-coated tablet * Concentration: 10 mg * Route of Administration: Oral use

  • * Active Substance: Brivaracetam * Pharmaceutical Form: Film-coated tablet * Concentration: 25 mg * Route of Administration: Oral use

06

What researchers measure

Primary outcomes

  1. Partial Onset Seizure (Type I) Frequency Per Week Over the 12-week Treatment Period

    Partial (Type I) seizures can be classified into one of the following three groups: * Simple partial seizures * Complex partial seizures * Partial seizures evolving to generalized tonic-clonic convulsions. Partial Onset Seizure (POS) Frequency per week over the Treatment Period (TP) was calculated as: (Total Type I seizures over the TP)\*7/(Total number of days with no missing seizure count in the TP)

    Time frame: Baseline to 12-week Treatment Period

Secondary outcomes

  1. Responder Rate for Partial Onset Seizure (Type I) Frequency Per Week Over the 12-week Treatment Period

    The responder rate was presented as the number of responders and non-responders. A subject is a responder, if the subject has at least 50 % reduction in partial onset seizure frequency per week from Baseline to Treatment Period. Subjects with zero seizure frequency per week at Baseline were considered as non-responders.

    Time frame: Baseline to 12-week Treatment Period

  2. All Seizure Frequency (Type I+II+III) Per Week Over the 12-week Treatment Period

    There are three different types of seizures: * Type I: Partial seizures * Type II: Generalized seizures * Type III: Unclassified epileptic seizures. All seizure frequency per week over Treatment Period (TP) was calculated as: (Total number of seizures over the TP)\*7/(Total number of days with no missing seizure count in the TP)

    Time frame: Baseline to 12-week Treatment Period

  3. Percent Change From Baseline to the 12-week Treatment Period in Partial Onset Seizure (Type I) Frequency Per Week

    Percent change from Baseline was calculated as percent reduction by: (weekly seizure frequency Baseline - weekly seizure frequency Treatment)\*100/(weekly seizure frequency Baseline). The higher the values for percent change in Partial Onset Seizure (POS) frequency, the higher the improvement from Baseline.

    Time frame: Baseline to 12-week Treatment Period

  4. Categorized Percentage Change From Baseline in Seizure Frequency for Partial Onset Seizure (Type I) Over the 12-week Treatment Period

    Subjects were classified in 1 of the following categories based on their percent reduction from Baseline to Treatment Period in Partial Onset Seizure (POS) frequency per week: \<-25 %, -25 % to \<25 %, 25 % to \<50 %, 50 % to \<75 %, 75 % to \<100 %, and 100 %. Subjects having zero for Baseline seizure frequency per week were classified in the \<-25 % category.

    Time frame: Baseline to 12-week Treatment Period

  5. Seizure Freedom Rate (All Seizure Types) Over the 12-week Treatment Period

    Subjects were considered seizure free if their seizure counts for every day over the Treatment Period (TP) was zero and if they did not discontinue before the end of the TP. Seizure freedom rate was calculated as: (total number of seizure - free subjects in treatment group during TP)/(total number of evaluable Intent-To-Treat (ITT) subjects in treatment group)

    Time frame: Baseline to 12-week Treatment Period

  6. Time to First Type I Seizure During the 12-week Treatment Period

    The time to first Partial Onset Seizure (POS) in the Treatment Period is defined as the time between beginning of the Treatment Period and the date of occurrence of first Type I seizure. Subjects withdrawing during the Treatment Period before having a first Type I seizure were considered as having a first Type I seizure on the last day of their Treatment Period.

    Time frame: Baseline to 12-week Treatment Period

  7. Time to Fifth Type I Seizure During the 12-week Treatment Period

    The time to fifth Partial Onset Seizure (POS) in the Treatment Period is defined as the time between beginning of the Treatment Period and the date of occurrence of fifth Type I seizure. Subjects withdrawing during the Treatment Period before having a fifth Type I seizure were considered as having a fifth Type I seizure on the last day of their Treatment Period.

    Time frame: Baseline to 12-week Treatment Period

  8. Time to Tenth Type I Seizure During the 12-week Treatment Period

    The time to tenth Partial Onset Seizure (POS) in the Treatment Period is defined as the time between beginning of the Treatment Period and the date of occurrence of tenth Type I seizure. Subjects withdrawing during the Treatment Period before having a tenth Type I seizure were considered as having a tenth Type I seizure on the last day of their Treatment Period.

    Time frame: Baseline to 12-week Treatment Period

  9. Reduction of Type IC/Type I Seizure Frequency Ratio From Baseline to the 12- Week Treatment Period

    The type IC/Type I seizure frequency ratio is represented by the percentage of subjects having a reduction in the ratio of Type IC seizure frequency over Type IA, IB, and IC seizure frequency from Baseline to Treatment Period.

    Time frame: Baseline to 12-week Treatment Period

  10. Change From Baseline to the 12-week Treatment Period in Total Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score

    The Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-items subscales - seizure worry (5 items), overall quality of life (2 items), emotional well-being (5 items), energy / fatigue (4 items), cognitive functioning (6 items), medication effects (3 items), and social function (5 items) - and a health status item. The subscale scores, the total score and the health status item score range from 0 to 100 and higher scores indicating better function.

    Time frame: Baseline to 12-week Treatment Period

  11. Change From Baseline to the 12-week Treatment Period in Seizure Worry Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score

    The Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-items subscales - seizure worry (5 items), overall quality of life (2 items), emotional well-being (5 items), energy / fatigue (4 items), cognitive functioning (6 items), medication effects (3 items), and social function (5 items) - and a health status item. The subscale scores, the total score and the health status item score range from 0 to 100 and higher scores indicating better function.

    Time frame: Baseline to 12-week Treatment Period

  12. Change From Baseline to the 12-week Treatment Period in Daily Activities / Social Functioning Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score

    The Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-items subscales - seizure worry (5 items), overall quality of life (2 items), emotional well-being (5 items), energy / fatigue (4 items), cognitive functioning (6 items), medication effects (3 items), and social function (5 items) - and a health status item. The subscale scores, the total score and the health status item score range from 0 to 100 and higher scores indicating better function.

    Time frame: Baseline to 12-week Treatment Period

  13. Change From Baseline to the 12-week Treatment Period in Hospital Anxiety Score

    The Hospital Anxiety and Depression Scale (HADS) was used to evaluate anxiety and depression. The HADS was developed as a self administered scale to assess the presence and severity of both anxiety and depression simultaneously. It consists of 14 items that are scored on a 4-point severity scale ranging from 0 to 3. A score per dimension was calculated with each score ranging from 0 to 21 and higher scores indicating higher depression / anxiety. A negative value in change from Baseline shows an improvement in HADS from Baseline.

    Time frame: Baseline to 12-week Treatment Period

  14. Change From Baseline to the 12-week Treatment Period in Hospital Depression Score

    The Hospital Anxiety and Depression Scale (HADS) was used to evaluate anxiety and depression. The HADS was developed as a self administered scale to assess the presence and severity of both anxiety and depression simultaneously. It consists of 14 items that are scored on a 4-point severity scale ranging from 0 to 3. A score per dimension was calculated with each score ranging from 0 to 21 and higher scores indicating higher depression / anxiety. A negative value in change from Baseline shows an improvement in HADS from Baseline.

    Time frame: Baseline to 12-week Treatment Period

  15. Patient's Global Evaluation Scale (P-GES) Evaluated at Last Visit or Early Discontinuation Visit

    Patient's Global Evaluation Scale (P-GES) is a global assessment of the disease evolution which was performed using a seven-point scale (1= Marked worsening to 7 = Marked improvement) with the start of the study medication as the reference time point. The subject completed it by answering to the following: 'Overall, has there been a change in your seizures since the start of the study medication?'

    Time frame: Baseline to Last Visit or Early Discontinuation Visit in the 12-week Treatment Period

  16. Investigator's Global Evaluation Scale (I-GES) Evaluated at Last Visit or Early Discontinuation Visit

    The Investigator's Global Evaluation Scale (I-GES) is a global assessment of the disease evolution which was performed using a seven-point scale (1 = Marked worsening to 7 = Marked improvement) with the start of the study medication as the reference time point. The investigator completed it by answering to the following: 'Assess the overall change in the severity of patient's illness, compared to start of study medication.'

    Time frame: Baseline to Last Visit or Early Discontinuation Visit in the 12-week Treatment Period

  17. Change From Baseline to the 12-week Treatment Period in Energy/Fatigue Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score

    The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.

    Time frame: From Baseline to 12-week Treatment Period

  18. Change From Baseline to the 12-week Treatment Period in Emotional Well-Being Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score

    The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.

    Time frame: From Baseline to 12-week Treatment Period

  19. Change From Baseline to the 12-week Treatment Period in Cognitive Functioning Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score

    The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.

    Time frame: From Baseline to 12-week Treatment Period

  20. Change From Baseline to the 12-week Treatment Period in Medication Effects Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score

    The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.

    Time frame: From Baseline to 12-week Treatment Period

  21. Change From Baseline to the 12-week Treatment Period in Overall Quality of Life Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score

    The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.

    Time frame: From Baseline to 12-week Treatment Period

  22. Change From Baseline to the 12-week Treatment Period in Health Status of Life Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score

    The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.

    Time frame: From Baseline to 12-week Treatment Period

07

Results

Posted Apr 13, 2016

Participant flow

This study started to enroll subjects in September 2007 and concluded in January 2009. 400 subjects were randomized of which 396 are included in the Safety Population.

Participant flow — Overall Study
MilestonePlaceboBRV 5 mg/DayBRV 20 mg/DayBRV 50 mg/Day
Started9999100102
Completed93829393
Not completed61779
Withdrew: Lack of efficacy1000
Withdrew: Lost to follow-up0401
Withdrew: Withdrawal by subject0211
Withdrew: Other reason3311
Withdrew: Ae, serious fatal0011
Withdrew: Sae, non-fatal0001
Withdrew: Ae, non-serious non-fatal2834
Withdrew: Sae,non-fatal+ae,non-serious non-fatal0010

Outcome measures

PrimaryPartial Onset Seizure (Type I) Frequency Per Week Over the 12-week Treatment Period

Partial (Type I) seizures can be classified into one of the following three groups: * Simple partial seizures * Complex partial seizures * Partial seizures evolving to generalized tonic-clonic convulsions. Partial Onset Seizure (POS) Frequency per week over the Treatment Period (TP) was calculated as: (Total Type I seizures over the TP)\*7/(Total number of days with no missing seizure count in the TP)

Time frame:
Baseline to 12-week Treatment Period
Reported as:
Median · seizures per week
Partial Onset Seizure (Type I) Frequency Per Week Over the 12-week Treatment Period
seizures per weekModified Intention-to-Treat (Placebo Treated Subjects)Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects)Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects)Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects)
Partial Onset Seizure (Type I) Frequency Per Week Over the 12-week Treatment Period2.15 (1.43 to 4.15)1.80 (0.99 to 5.59)1.96 (1.05 to 5.45)1.70 (0.91 to 4.80)
Statistical analysis
  • Modified Intention-to-Treat (Placebo Treated Subjects) vs Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) · ANCOVA · p = =0.025 · % reduction over placebo: 12.8 · 95% CI 1.7 to 22.6The log-transformed (log(x+1)) POS seizure frequency was analyzed using an ANCOVA model, including terms for treatment, stratification factors, and log-transformed Baseline POS seizure frequency per week as a covariate.
  • Modified Intention-to-Treat (Placebo Treated Subjects) vs Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) · ANCOVA · p = =0.492 · % reduction over placebo: 4.1 · 95% CI -8.1 to 15.0The log-transformed (log(x+1)) POS seizure frequency was analyzed using an ANCOVA model, including terms for treatment, stratification factors, and log-transformed Baseline POS seizure frequency per week as a covariate.
SecondaryResponder Rate for Partial Onset Seizure (Type I) Frequency Per Week Over the 12-week Treatment Period

The responder rate was presented as the number of responders and non-responders. A subject is a responder, if the subject has at least 50 % reduction in partial onset seizure frequency per week from Baseline to Treatment Period. Subjects with zero seizure frequency per week at Baseline were considered as non-responders.

Time frame:
Baseline to 12-week Treatment Period
Reported as:
Number · participants
Responder Rate for Partial Onset Seizure (Type I) Frequency Per Week Over the 12-week Treatment Period
participantsModified Intention-to-Treat (Placebo Treated Subjects)Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects)Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects)Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects)
Responders16212333
Non-responders80757668
SecondaryAll Seizure Frequency (Type I+II+III) Per Week Over the 12-week Treatment Period

There are three different types of seizures: * Type I: Partial seizures * Type II: Generalized seizures * Type III: Unclassified epileptic seizures. All seizure frequency per week over Treatment Period (TP) was calculated as: (Total number of seizures over the TP)\*7/(Total number of days with no missing seizure count in the TP)

Time frame:
Baseline to 12-week Treatment Period
Reported as:
Median · seizures per week
All Seizure Frequency (Type I+II+III) Per Week Over the 12-week Treatment Period
seizures per weekModified Intention-to-Treat (Placebo Treated Subjects)Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects)Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects)Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects)
All Seizure Frequency (Type I+II+III) Per Week Over the 12-week Treatment Period2.15 (1.45 to 4.23)1.80 (0.99 to 5.59)1.96 (1.05 to 5.85)1.77 (0.99 to 4.80)
SecondaryPercent Change From Baseline to the 12-week Treatment Period in Partial Onset Seizure (Type I) Frequency Per Week

Percent change from Baseline was calculated as percent reduction by: (weekly seizure frequency Baseline - weekly seizure frequency Treatment)\*100/(weekly seizure frequency Baseline). The higher the values for percent change in Partial Onset Seizure (POS) frequency, the higher the improvement from Baseline.

Time frame:
Baseline to 12-week Treatment Period
Reported as:
Median · Percent change in POS frequency
Percent Change From Baseline to the 12-week Treatment Period in Partial Onset Seizure (Type I) Frequency Per Week
Percent change in POS frequencyModified Intention-to-Treat (Placebo Treated Subjects)Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects)Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects)Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects)
Percent Change From Baseline to the 12-week Treatment Period in Partial Onset Seizure (Type I) Frequency Per Week17.75 (-5.11 to 37.07)19.95 (-12.96 to 45.15)22.52 (-4.56 to 46.51)30.47 (11.40 to 59.78)
SecondaryCategorized Percentage Change From Baseline in Seizure Frequency for Partial Onset Seizure (Type I) Over the 12-week Treatment Period

Subjects were classified in 1 of the following categories based on their percent reduction from Baseline to Treatment Period in Partial Onset Seizure (POS) frequency per week: \<-25 %, -25 % to \<25 %, 25 % to \<50 %, 50 % to \<75 %, 75 % to \<100 %, and 100 %. Subjects having zero for Baseline seizure frequency per week were classified in the \<-25 % category.

Time frame:
Baseline to 12-week Treatment Period
Reported as:
Number · percentage of participants
Categorized Percentage Change From Baseline in Seizure Frequency for Partial Onset Seizure (Type I) Over the 12-week Treatment Period
percentage of participantsModified Intention-to-Treat (Placebo Treated Subjects)Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects)Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects)Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects)
<-25 %14.621.914.19.9
-25 % to < 25 %44.831.338.431.7
25 % to < 50 %24.025.024.225.7
50 % to < 75 %12.512.515.219.8
75 % to < 100 %4.28.36.18.9
100 %01.02.04.0
SecondarySeizure Freedom Rate (All Seizure Types) Over the 12-week Treatment Period

Subjects were considered seizure free if their seizure counts for every day over the Treatment Period (TP) was zero and if they did not discontinue before the end of the TP. Seizure freedom rate was calculated as: (total number of seizure - free subjects in treatment group during TP)/(total number of evaluable Intent-To-Treat (ITT) subjects in treatment group)

Time frame:
Baseline to 12-week Treatment Period
Reported as:
Number · percentage of participants
Seizure Freedom Rate (All Seizure Types) Over the 12-week Treatment Period
percentage of participantsModified Intention-to-Treat (Placebo Treated Subjects)Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects)Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects)Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects)
Seizure-free01.01.04.0
No seizures but non-completer001.00
Not seizure-free100.099.098.096.0
SecondaryTime to First Type I Seizure During the 12-week Treatment Period

The time to first Partial Onset Seizure (POS) in the Treatment Period is defined as the time between beginning of the Treatment Period and the date of occurrence of first Type I seizure. Subjects withdrawing during the Treatment Period before having a first Type I seizure were considered as having a first Type I seizure on the last day of their Treatment Period.

Time frame:
Baseline to 12-week Treatment Period
Reported as:
Median · days
Time to First Type I Seizure During the 12-week Treatment Period
daysModified Intention-to-Treat (Placebo Treated Subjects)Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects)Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects)Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects)
Time to First Type I Seizure During the 12-week Treatment Period3 (2 to 3)4 (2 to 5)5 (3 to 7)4 (3 to 6)
SecondaryTime to Fifth Type I Seizure During the 12-week Treatment Period

The time to fifth Partial Onset Seizure (POS) in the Treatment Period is defined as the time between beginning of the Treatment Period and the date of occurrence of fifth Type I seizure. Subjects withdrawing during the Treatment Period before having a fifth Type I seizure were considered as having a fifth Type I seizure on the last day of their Treatment Period.

Time frame:
Baseline to 12-week Treatment Period
Reported as:
Median · days
Time to Fifth Type I Seizure During the 12-week Treatment Period
daysModified Intention-to-Treat (Placebo Treated Subjects)Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects)Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects)Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects)
Time to Fifth Type I Seizure During the 12-week Treatment Period15 (12 to 16)14 (12 to 18)17 (14 to 21)19 (16 to 25)
SecondaryTime to Tenth Type I Seizure During the 12-week Treatment Period

The time to tenth Partial Onset Seizure (POS) in the Treatment Period is defined as the time between beginning of the Treatment Period and the date of occurrence of tenth Type I seizure. Subjects withdrawing during the Treatment Period before having a tenth Type I seizure were considered as having a tenth Type I seizure on the last day of their Treatment Period.

Time frame:
Baseline to 12-week Treatment Period
Reported as:
Median · days
Time to Tenth Type I Seizure During the 12-week Treatment Period
daysModified Intention-to-Treat (Placebo Treated Subjects)Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects)Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects)Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects)
Time to Tenth Type I Seizure During the 12-week Treatment Period28 (24 to 33)30 (21 to 38)34 (25 to 46)37 (27 to 52)
SecondaryReduction of Type IC/Type I Seizure Frequency Ratio From Baseline to the 12- Week Treatment Period

The type IC/Type I seizure frequency ratio is represented by the percentage of subjects having a reduction in the ratio of Type IC seizure frequency over Type IA, IB, and IC seizure frequency from Baseline to Treatment Period.

Time frame:
Baseline to 12-week Treatment Period
Reported as:
Number · percentage of participants
Reduction of Type IC/Type I Seizure Frequency Ratio From Baseline to the 12- Week Treatment Period
percentage of participantsModified Intention-to-Treat (Placebo Treated Subjects)Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects)Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects)Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects)
Reduction of Type IC/Type I Seizure Frequency Ratio From Baseline to the 12- Week Treatment Period56.350.077.863.6
SecondaryChange From Baseline to the 12-week Treatment Period in Total Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score

The Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-items subscales - seizure worry (5 items), overall quality of life (2 items), emotional well-being (5 items), energy / fatigue (4 items), cognitive functioning (6 items), medication effects (3 items), and social function (5 items) - and a health status item. The subscale scores, the total score and the health status item score range from 0 to 100 and higher scores indicating better function.

Time frame:
Baseline to 12-week Treatment Period
Reported as:
Mean · units on a scale
Change From Baseline to the 12-week Treatment Period in Total Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score
units on a scaleModified Intention-to-Treat (Placebo Treated Subjects)Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects)Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects)Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects)
Change From Baseline to the 12-week Treatment Period in Total Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score3.88 ± 14.444.07 ± 15.405.19 ± 15.472.88 ± 13.53
SecondaryChange From Baseline to the 12-week Treatment Period in Seizure Worry Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score

The Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-items subscales - seizure worry (5 items), overall quality of life (2 items), emotional well-being (5 items), energy / fatigue (4 items), cognitive functioning (6 items), medication effects (3 items), and social function (5 items) - and a health status item. The subscale scores, the total score and the health status item score range from 0 to 100 and higher scores indicating better function.

Time frame:
Baseline to 12-week Treatment Period
Reported as:
Mean · units on a scale
Change From Baseline to the 12-week Treatment Period in Seizure Worry Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score
units on a scaleModified Intention-to-Treat (Placebo Treated Subjects)Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects)Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects)Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects)
Change From Baseline to the 12-week Treatment Period in Seizure Worry Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score9.36 ± 26.983.34 ± 19.203.69 ± 24.555.97 ± 21.79
SecondaryChange From Baseline to the 12-week Treatment Period in Daily Activities / Social Functioning Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score

The Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-items subscales - seizure worry (5 items), overall quality of life (2 items), emotional well-being (5 items), energy / fatigue (4 items), cognitive functioning (6 items), medication effects (3 items), and social function (5 items) - and a health status item. The subscale scores, the total score and the health status item score range from 0 to 100 and higher scores indicating better function.

Time frame:
Baseline to 12-week Treatment Period
Reported as:
Mean · units on a scale
Change From Baseline to the 12-week Treatment Period in Daily Activities / Social Functioning Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score
units on a scaleModified Intention-to-Treat (Placebo Treated Subjects)Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects)Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects)Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects)
Change From Baseline to the 12-week Treatment Period in Daily Activities / Social Functioning Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score1.97 ± 28.397.03 ± 23.477.73 ± 26.042.06 ± 23.02
SecondaryChange From Baseline to the 12-week Treatment Period in Hospital Anxiety Score

The Hospital Anxiety and Depression Scale (HADS) was used to evaluate anxiety and depression. The HADS was developed as a self administered scale to assess the presence and severity of both anxiety and depression simultaneously. It consists of 14 items that are scored on a 4-point severity scale ranging from 0 to 3. A score per dimension was calculated with each score ranging from 0 to 21 and higher scores indicating higher depression / anxiety. A negative value in change from Baseline shows an improvement in HADS from Baseline.

Time frame:
Baseline to 12-week Treatment Period
Reported as:
Mean · units on a scale
Change From Baseline to the 12-week Treatment Period in Hospital Anxiety Score
units on a scaleModified Intention-to-Treat (Placebo Treated Subjects)Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects)Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects)Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects)
Change From Baseline to the 12-week Treatment Period in Hospital Anxiety Score7.44 ± 4.327.32 ± 4.036.55 ± 3.947.99 ± 3.63
SecondaryChange From Baseline to the 12-week Treatment Period in Hospital Depression Score

The Hospital Anxiety and Depression Scale (HADS) was used to evaluate anxiety and depression. The HADS was developed as a self administered scale to assess the presence and severity of both anxiety and depression simultaneously. It consists of 14 items that are scored on a 4-point severity scale ranging from 0 to 3. A score per dimension was calculated with each score ranging from 0 to 21 and higher scores indicating higher depression / anxiety. A negative value in change from Baseline shows an improvement in HADS from Baseline.

Time frame:
Baseline to 12-week Treatment Period
Reported as:
Mean · units on a scale
Change From Baseline to the 12-week Treatment Period in Hospital Depression Score
units on a scaleModified Intention-to-Treat (Placebo Treated Subjects)Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects)Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects)Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects)
Change From Baseline to the 12-week Treatment Period in Hospital Depression Score5.36 ± 3.784.97 ± 4.004.82 ± 3.565.81 ± 3.70
SecondaryPatient's Global Evaluation Scale (P-GES) Evaluated at Last Visit or Early Discontinuation Visit

Patient's Global Evaluation Scale (P-GES) is a global assessment of the disease evolution which was performed using a seven-point scale (1= Marked worsening to 7 = Marked improvement) with the start of the study medication as the reference time point. The subject completed it by answering to the following: 'Overall, has there been a change in your seizures since the start of the study medication?'

Time frame:
Baseline to Last Visit or Early Discontinuation Visit in the 12-week Treatment Period
Reported as:
Number · percentage of participants
Patient's Global Evaluation Scale (P-GES) Evaluated at Last Visit or Early Discontinuation Visit
percentage of participantsModified Intention-to-Treat (Placebo Treated Subjects)Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects)Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects)Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects)
Marked improvement15.519.818.826.7
Moderate improvement25.024.726.319.8
Slight improvement23.818.521.322.1
No change28.623.527.523.3
Slight worsening4.86.21.34.7
Moderate worsening1.27.43.81.2
Marked worsening1.201.32.3
SecondaryInvestigator's Global Evaluation Scale (I-GES) Evaluated at Last Visit or Early Discontinuation Visit

The Investigator's Global Evaluation Scale (I-GES) is a global assessment of the disease evolution which was performed using a seven-point scale (1 = Marked worsening to 7 = Marked improvement) with the start of the study medication as the reference time point. The investigator completed it by answering to the following: 'Assess the overall change in the severity of patient's illness, compared to start of study medication.'

Time frame:
Baseline to Last Visit or Early Discontinuation Visit in the 12-week Treatment Period
Reported as:
Number · percentage of participants
Investigator's Global Evaluation Scale (I-GES) Evaluated at Last Visit or Early Discontinuation Visit
percentage of participantsModified Intention-to-Treat (Placebo Treated Subjects)Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects)Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects)Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects)
Marked improvement12.612.217.216.3
Moderate improvement20.018.918.227.6
Slight improvement21.124.431.324.5
No change41.134.432.325.5
Slight worsening3.22.21.02.0
Moderate worsening1.17.803.1
Marked worsening1.1001.0
SecondaryChange From Baseline to the 12-week Treatment Period in Energy/Fatigue Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score

The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.

Time frame:
From Baseline to 12-week Treatment Period
Reported as:
Mean · units on a scale
Change From Baseline to the 12-week Treatment Period in Energy/Fatigue Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score
units on a scaleModified Intention-to-Treat (Placebo Treated Subjects)Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects)Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects)Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects)
Change From Baseline to the 12-week Treatment Period in Energy/Fatigue Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score6.41 ± 19.552.24 ± 23.103.94 ± 15.560.45 ± 20.07
SecondaryChange From Baseline to the 12-week Treatment Period in Emotional Well-Being Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score

The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.

Time frame:
From Baseline to 12-week Treatment Period
Reported as:
Mean · units on a scale
Change From Baseline to the 12-week Treatment Period in Emotional Well-Being Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score
units on a scaleModified Intention-to-Treat (Placebo Treated Subjects)Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects)Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects)Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects)
Change From Baseline to the 12-week Treatment Period in Emotional Well-Being Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score2.14 ± 18.281.69 ± 21.612.07 ± 19.101.97 ± 17.29
SecondaryChange From Baseline to the 12-week Treatment Period in Cognitive Functioning Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score

The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.

Time frame:
From Baseline to 12-week Treatment Period
Reported as:
Mean · units on a scale
Change From Baseline to the 12-week Treatment Period in Cognitive Functioning Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score
units on a scaleModified Intention-to-Treat (Placebo Treated Subjects)Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects)Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects)Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects)
Change From Baseline to the 12-week Treatment Period in Cognitive Functioning Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score2.79 ± 20.344.26 ± 21.236.36 ± 24.613.37 ± 19.16
SecondaryChange From Baseline to the 12-week Treatment Period in Medication Effects Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score

The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.

Time frame:
From Baseline to 12-week Treatment Period
Reported as:
Mean · units on a scale
Change From Baseline to the 12-week Treatment Period in Medication Effects Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score
units on a scaleModified Intention-to-Treat (Placebo Treated Subjects)Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects)Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects)Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects)
Change From Baseline to the 12-week Treatment Period in Medication Effects Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score1.02 ± 34.05-2.61 ± 28.080.73 ± 25.946.07 ± 30.90
SecondaryChange From Baseline to the 12-week Treatment Period in Overall Quality of Life Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score

The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.

Time frame:
From Baseline to 12-week Treatment Period
Reported as:
Mean · units on a scale
Change From Baseline to the 12-week Treatment Period in Overall Quality of Life Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score
units on a scaleModified Intention-to-Treat (Placebo Treated Subjects)Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects)Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects)Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects)
Change From Baseline to the 12-week Treatment Period in Overall Quality of Life Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score5.49 ± 16.253.39 ± 19.703.66 ± 20.102.33 ± 19.14
SecondaryChange From Baseline to the 12-week Treatment Period in Health Status of Life Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score

The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.

Time frame:
From Baseline to 12-week Treatment Period
Reported as:
Mean · units on a scale
Change From Baseline to the 12-week Treatment Period in Health Status of Life Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score
units on a scaleModified Intention-to-Treat (Placebo Treated Subjects)Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects)Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects)Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects)
Change From Baseline to the 12-week Treatment Period in Health Status of Life Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score8.1 ± 22.06.9 ± 23.57.3 ± 21.15.5 ± 20.9

Adverse events

Collected over Adverse Events (AEs) were collected up to 23 weeks from Visit 1 (Week -8) to the Safety Visit (Week 15).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—0/98 (0%)32/98 (32.7%)
BRV 5 mg/Day—1/97 (1%)49/97 (50.5%)
BRV 20 mg/Day—3/100 (3%)46/100 (46%)
BRV 50 mg/Day—4/101 (4%)51/101 (50.5%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventPlaceboBRV 5 mg/DayBRV 20 mg/DayBRV 50 mg/Day
PneumoniaInfections and infestations0/981/970/1000/101
SyncopeNervous system disorders0/980/971/1000/101
Aspiration bronchialRespiratory, thoracic and mediastinal disorders0/980/971/1000/101
BronchospasmRespiratory, thoracic and mediastinal disorders0/980/971/1000/101
Respiratory failureRespiratory, thoracic and mediastinal disorders0/980/971/1000/101
Abdominal painGastrointestinal disorders0/980/970/1001/101
VomitingGastrointestinal disorders0/980/970/1001/101
Chest painGeneral disorders0/980/970/1001/101
PainGeneral disorders0/980/970/1001/101
BronchitisInfections and infestations0/980/970/1001/101
Most frequent other events
Most frequent other events
EventPlaceboBRV 5 mg/DayBRV 20 mg/DayBRV 50 mg/Day
SomnolenceNervous system disorders7/9814/9714/10017/101
DizzinessNervous system disorders9/9812/9714/10016/101
HeadacheNervous system disorders14/9811/976/10013/101
FatigueGeneral disorders2/983/9713/10010/101
InfluenzaInfections and infestations1/989/976/1004/101
NauseaGastrointestinal disorders3/984/977/1006/101
InsomniaPsychiatric disorders2/982/973/1007/101
Urinary tract infectionInfections and infestations2/983/976/1001/101
DiarrhoeaGastrointestinal disorders2/984/974/1006/101
Upper respiratory tract infectionInfections and infestations4/985/975/1000/101

Baseline characteristics

Baseline Characteristics refer to Randomized Set.

Age, Continuous
Age, Continuous(years)PlaceboBRV 5 mg/DayBRV 20 mg/DayBRV 50 mg/DayTotal Title
Mean37.6 ± 12.638.8 ± 11.637.3 ± 13.339.0 ± 12.338.2 ± 12.5
Age, Customized
Age, Customized(participants)PlaceboBRV 5 mg/DayBRV 20 mg/DayBRV 50 mg/DayTotal Title
< 18 years705214
18 - < 65 years91979399380
65 - < 85 years12216
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboBRV 5 mg/DayBRV 20 mg/DayBRV 50 mg/DayTotal Title
Female55494850202
Male44505252198
08

Study locations

70 sites
  • Phoenix, Arizona, United States
  • Tucson, Arizona, United States
  • Little Rock, Arkansas, United States
  • Fresno, California, United States
  • Los Angeles, California, United States
  • Newport Beach, California, United States
  • Sacramento, California, United States
  • San Francisco, California, United States
  • Washington, District of Columbia, United States
  • Atlanta, Georgia, United States
  • Augusta, Georgia, United States
  • Chicago, Illinois, United States
  • Springfield, Illinois, United States
  • Wichita, Kansas, United States
  • Lexington, Kentucky, United States
  • Louisville, Kentucky, United States
  • Baltimore, Maryland, United States
  • Bethesda, Maryland, United States
  • Burlington, Massachusetts, United States
  • Detroit, Michigan, United States
  • Grand Rapids, Michigan, United States
  • Saint Paul, Minnesota, United States
  • Tupelo, Mississippi, United States
  • Chesterfield, Missouri, United States
  • Saint Louis, Missouri, United States
  • New York, New York, United States
  • Rochester, New York, United States
  • Cincinnati, Ohio, United States
  • Columbus, Ohio, United States
  • Portland, Oregon, United States
  • Philadelphia, Pennsylvania, United States
  • Greenville, South Carolina, United States
  • Nashville, Tennessee, United States
  • Dallas, Texas, United States
  • Houston, Texas, United States
  • Salt Lake City, Utah, United States
  • Charlottesville, Virginia, United States
  • Richmond, Virginia, United States
  • Seattle, Washington, United States
  • Milwaukee, Wisconsin, United States
  • Chatswood, New South Wales, Australia
  • Randwick, New South Wales, Australia
  • Woodville, South Australia, Australia
  • Clayton, Victoria, Australia
  • Fitzroy, Victoria, Australia
  • Parkville, Victoria, Australia
  • Adelaide, Australia
  • Fitzroy, Australia
  • West Heidelberg, Australia
  • Campinas, Brazil
  • Curitiba, Brazil
  • Florianópolis, Brazil
  • Porto Alegre, Brazil
  • Ribeirao Preto, Brazil
  • Salvador, Brazil
  • Sao Jose do Rio Preto, Brazil
  • Sao Paulo, Brazil
  • São Paulo, Brazil
  • Edmonton, Alberta, Canada
  • Greenfield Park, Quebec, Canada
  • Montreal, Quebec, Canada
  • Quebec City, Quebec, Canada
  • Mexico, DF, Mexico
  • Monterrey, NL, Mexico
  • Aguascalientes, Mexico
  • Chihuahua, Mexico
  • Mexico DF, Mexico
  • Monterrey, Mexico
  • Nuevo León, Mexico
  • San Luis Potosi, Mexico
09

References and documents

Publications

  • Biton V, Berkovic SF, Abou-Khalil B, Sperling MR, Johnson ME, Lu S. Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial. Epilepsia. 2014 Jan;55(1):57-66. doi: 10.1111/epi.12433. Epub 2013 Nov 8. PubMed 24446953 ↗
  • Toledo M, Whitesides J, Schiemann J, Johnson ME, Eckhardt K, McDonough B, Borghs S, Kwan P. Safety, tolerability, and seizure control during long-term treatment with adjunctive brivaracetam for partial-onset seizures. Epilepsia. 2016 Jul;57(7):1139-51. doi: 10.1111/epi.13416. Epub 2016 Jun 6. PubMed 27265725 ↗
  • Ben-Menachem E, Mameniskiene R, Quarato PP, Klein P, Gamage J, Schiemann J, Johnson ME, Whitesides J, McDonough B, Eckhardt K. Efficacy and safety of brivaracetam for partial-onset seizures in 3 pooled clinical studies. Neurology. 2016 Jul 19;87(3):314-23. doi: 10.1212/WNL.0000000000002864. Epub 2016 Jun 22. PubMed 27335114 ↗
  • Brodie MJ, Whitesides J, Schiemann J, D'Souza J, Johnson ME. Tolerability, safety, and efficacy of adjunctive brivaracetam for focal seizures in older patients: A pooled analysis from three phase III studies. Epilepsy Res. 2016 Nov;127:114-118. doi: 10.1016/j.eplepsyres.2016.08.018. Epub 2016 Aug 18. PubMed 27589414 ↗
  • Mukuria C, Young T, Keetharuth A, Borghs S, Brazier J. Sensitivity and responsiveness of the EQ-5D-3L in patients with uncontrolled focal seizures: an analysis of Phase III trials of adjunctive brivaracetam. Qual Life Res. 2017 Mar;26(3):749-759. doi: 10.1007/s11136-016-1483-3. Epub 2016 Dec 21. PubMed 28004320 ↗
  • Moseley BD, Sperling MR, Asadi-Pooya AA, Diaz A, Elmouft S, Schiemann J, Whitesides J. Efficacy, safety, and tolerability of adjunctive brivaracetam for secondarily generalized tonic-clonic seizures: Pooled results from three Phase III studies. Epilepsy Res. 2016 Nov;127:179-185. doi: 10.1016/j.eplepsyres.2016.09.003. Epub 2016 Sep 3. PubMed 27608437 ↗
  • Brandt C, Borghs S, Elmoufti S, Mueller K, Townsend R, de la Loge C. Health-related quality of life in double-blind Phase III studies of brivaracetam as adjunctive therapy of focal seizures: A pooled, post-hoc analysis. Epilepsy Behav. 2017 Apr;69:80-85. doi: 10.1016/j.yebeh.2016.11.031. Epub 2017 Feb 23. PubMed 28236727 ↗
  • Klein P, Johnson ME, Schiemann J, Whitesides J. Time to onset of sustained >/=50% responder status in patients with focal (partial-onset) seizures in three phase III studies of adjunctive brivaracetam treatment. Epilepsia. 2017 Feb;58(2):e21-e25. doi: 10.1111/epi.13631. Epub 2016 Dec 18. PubMed 27988967 ↗
  • Asadi-Pooya AA, Sperling MR, Chung S, Klein P, Diaz A, Elmoufti S, Schiemann J, Whitesides J. Efficacy and tolerability of adjunctive brivaracetam in patients with prior antiepileptic drug exposure: A post-hoc study. Epilepsy Res. 2017 Mar;131:70-75. doi: 10.1016/j.eplepsyres.2017.02.007. Epub 2017 Feb 27. Erratum In: Epilepsy Res. 2017 Nov;137:165-166. doi: 10.1016/j.eplepsyres.2017.04.019. PubMed 28279891 ↗
  • Benbadis S, Klein P, Schiemann J, Diaz A, Elmoufti S, Whitesides J. Efficacy, safety, and tolerability of brivaracetam with concomitant lamotrigine or concomitant topiramate in pooled Phase III randomized, double-blind trials: A post-hoc analysis. Epilepsy Behav. 2018 Mar;80:129-134. doi: 10.1016/j.yebeh.2017.12.024. Epub 2018 Feb 3. PubMed 29414542 ↗
  • Brodie MJ, Fakhoury T, McDonough B, Colson AO, Stockis A, Elmoufti S, Whitesides J. Brivaracetam-induced elevation of carbamazepine epoxide levels: A post-hoc analysis from the clinical development program. Epilepsy Res. 2018 Sep;145:55-62. doi: 10.1016/j.eplepsyres.2018.06.002. Epub 2018 Jun 4. PubMed 29908435 ↗
  • Klein P, Laloyaux C, Elmoufti S, Gasalla T, Martin MS. Time course of 75%-100% efficacy response of adjunctive brivaracetam. Acta Neurol Scand. 2020 Aug;142(2):175-180. doi: 10.1111/ane.13287. Epub 2020 Jun 9. PubMed 32432339 ↗
  • Moseley BD, Dimova S, Elmoufti S, Laloyaux C, Asadi-Pooya AA. Long-term efficacy and tolerability of adjunctive brivaracetam in adults with focal to bilateral tonic-clonic (secondary generalized) seizures: Post hoc pooled analysis. Epilepsy Res. 2021 Oct;176:106694. doi: 10.1016/j.eplepsyres.2021.106694. Epub 2021 Jun 24. PubMed 34218211 ↗
  • Ryvlin P, Dimova S, Elmoufti S, Floricel F, Laloyaux C, Nondonfaz X, Biton V. Tolerability and efficacy of adjunctive brivaracetam in adults with focal seizures by concomitant antiseizure medication use: Pooled results from three phase 3 trials. Epilepsia. 2022 Aug;63(8):2024-2036. doi: 10.1111/epi.17304. Epub 2022 Jun 10. PubMed 35582748 ↗
  • Bresnahan R, Panebianco M, Marson AG. Brivaracetam add-on therapy for drug-resistant epilepsy. Cochrane Database Syst Rev. 2022 Mar 14;3(3):CD011501. doi: 10.1002/14651858.CD011501.pub3. PubMed 35285519 ↗
  • Lee SK, Heo K, Kim SE, Lee SA, Elmoufti S, Laloyaux C, Hur B. Effect of Number of Previous Antiseizure Medications on Efficacy and Tolerability of Adjunctive Brivaracetam for Uncontrolled Focal Seizures: Post Hoc Analysis. Adv Ther. 2021 Jul;38(7):4082-4099. doi: 10.1007/s12325-021-01816-5. Epub 2021 Jun 21. PubMed 34155568 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2007, a primary completion of Dec 2008 and a completion of Jan 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2016, 7 years 4 months after primary completion. A results delay was requested in Feb 2010.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 19, 2007
First posted
Apr 23, 2007
Start
Sep 2007
Primary completionActual
Dec 2008
CompletionActual
Jan 2009
Results delay requested
Feb 1, 2010
Results first posted
Apr 13, 2016
Last update
Jul 21, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00464269
Lead sponsor
UCB Pharma
Responsible party
Sponsor
First posted
Apr 23, 2007
Start date
Sep 2007
Primary completion
Dec 2008
Completion
Jan 2009
Results posted
Apr 13, 2016
Last update
Jul 21, 2022

Study contacts

UCB Clinical Trial Call Center
study director · +1 877 822 9493 (UCB)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brivaracetam

Start the discussion